Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Subgroup analyses of CLA supplementation on glycemic control, adipokine, cytokine, malondialdehyde and liver function enzymes in subjects with metabolic disorders

From: The effects of conjugated linoleic acid supplementation on glycemic control, adipokines, cytokines, malondialdehyde and liver function enzymes in patients at risk of cardiovascular disease: a GRADE-assessed systematic review and dose–response meta-analysis

 

Number of effect size

WMD (95%CI)

P-value

heterogeneity

P heterogeneity

I2

P between sub-groups

Subgroup analyses of CLA on serum FBG (mg/dL)

Overall effect

12

4.49 (2.39, 6.59)

 < 0.001

 < 0.001

97.1%

 

Baseline FBG (mg/dl)

 ≥ 100

9

5.90 (1.40, 10.40)

0.010

 < 0.001

90.5%

0.205

 < 100

3

1.13 (-4.70, 6.96)

0.704

 < 0.001

94.6%

Trial duration (week)

 ≥ 12

7

6.24 (3.71, 8.77)

 < 0.001

 < 0.001

98.3%

0.040

 <12

5

1.07 (-3.17, 5.32)

0.620

0.065

54.8%

Intervention dose (g/day)

 ≥ 3

5

7.57 (-0.17, 15.33)

0.055

 < 0.001

94.8%

0.247

 <3

7

2.73 (0.04, 5.42)

0.046

 < 0.001

98.0%

Baselin BMI (kg/m2)

 Obese (> 30)

7

3.55 (-3.08, 10.18)

0.294

 < 0.001

93.5%

0.755

 Overweight (25–29.9)

5

4.70 (1.79, 7.61)

0.002

 < 0.001

98.6%

Sex

 Male

2

4.46 (0.92, 7.99)

0.013

0.120

58.7%

0.671

 Both

8

2.62 (0.17, 5.07)

0.036

 < 0.001

97.7%

 Female

2

8.27 (-23.21, 39.76)

0.607

 < 0.001

96.6%

Health status

 Metabolic syndrome

3

2.46 (-2.63, 7.55)

0.343

0.022

73.9%

0.012

 T2DM

5

10.50 (-0.57, 21.58)

0.063

 < 0.001

85.6%

 Hyperlipidemic

2

4.41 (1.05, 7.76)

0.010

 < 0.001

99.6%

 Hypertension

1

0.00 (-2.17, 2.17)

1.000

-

-

 NAFLD

1

-5.89 (-11.96, 0.18)

0.057

-

-

Subgroup analyses of CLA on serum fasting insulin (mU/L)

 Overall effect

12

0.16 (-0.69, 1.02)

0.702

0.828

0.0%

 

Trial duration (week)

 ≥ 12

7

0.26 (-0.77, 1.30)

0.613

0.619

0.0%

0.737

 <12

5

-0.04 (-1.57, 1.48)

0.951

0.718

0.0%

Intervention dose (g/day)

 ≥ 3

5

0.17 (-1.16, 1.50)

0.801

0.383

4.2%

0.802

 <3

7

-0.08 (-1.53, 1.37)

0.912

0.891

0.0%

Baselin BMI (kg/m2)

 Obese (> 30)

7

0.19 (-0.77, 1.16)

0.687

0.601

0.0%

0.891

 Overweight (25–29.9)

5

0.05 (-1.81, 1.91)

0.956

0.725

0.0%

Sex

 Male

2

3.62 (-6.42, 13.66)

0.480

0.351

0.0%

0.430

 Both

8

-0.43 (-1.77, 0.90)

0.523

0.811

0.0%

 Female

2

0.55 (-0.57, 1.68)

0.335

0.552

0.0%

Health status

 Metabolic syndrome

3

0.43 (-6.32, 7.20)

0.899

0.455

0.0%

0.998

 T2DM

5

0.06 (-1.17, 1.30)

0.923

0.305

17.3%

 Hyperlipidemic

2

-0.02 (-5.20, 5.16)

0.994

0.824

0.0%

 Hypertension

1

-2.00 (-16.74, 12.74)

0.790

-

-

 NAFLD

1

-0.16 (-2.57, 2.25)

0.897

-

-

Subgroup analyses of CLA on serum HbA1c (%)

 Overall effect

6

-0.03 (-0.17, 0.09)

0.567

0.038

57.6%

 

Baseline HbA1c (%)

 < 6.5

3

0.05 (-0.22, 0.11)

0.529

0.004

82.3%

0.989

 ≥ 6.5

3

-0.05 (-0.40, 0.28)

0.748

0.841

0.0%

Trial duration (week)

 ≥ 12

3

0.02 (-0.03, 0.08)

0.385

0.587

0.0%

0.138

 <12

3

-0.30 (-0.73, 0.12)

0.167

0.120

52.9%

Intervention dose (g/day)

 ≥ 3

3

0.02 (-0.03, 0.08)

0.385

0.587

0.0%

0.138

 <3

3

-0.30 (-0.73, 0.12)

0.167

0.120

52.9%

Baselin BMI (kg/m2)

 Obese (> 30)

4

-0.04 (-0.20, 0.11)

0.575

0.010

73.4%

0.859

 Overweight (25–29.9)

2

-0.08 (-0.47, 0.31)

0.680

0.602

0.0%

Sex

 Male

2

0.02 (-0.03, 0.08)

0.397

0.302

6.1%

0.144

 Both

4

-0.25 (-0.61, 0.11)

0.178

0.157

42.4%

Health status

 Metabolic syndrome

2

0.02 (-0.03, 0.08)

0.397

0.302

6.1%

0.006

 T2DM

3

-0.05 (-0.40, 0.28)

0.748

0.841

0.0%

 NAFLD

1

-0.67 (-1.09, -0.24)

0.002

-

-

Subgroup analyses of CLA on serum HOMA-IR

 Overall effect

11

0.34 (-0.11, 0.81)

0.140

 < 0.001

78.7%

 

Trial duration (week)

 ≥ 12

5

0.23 (-0.56, 1.03)

0.563

 < 0.001

87.1%

0.702

 <12

6

0.43 (-0.18, 1.05)

0.171

0.007

68.4%

Intervention dose (g/day)

 ≥ 3

5

0.38 (-0.28, 1.05)

0.255

 < 0.001

86.7%

0.931

 <3

6

0.34 (-0.41, 1.10)

0.373

0.005

70.1%

Baselin BMI (kg/m2)

 Obese (> 30)

7

0.27 (-0.26, 0.81)

0.321

 < 0.001

81.0%

0.516

 Overweight (25–29.9)

4

0.69 (-0.46, 1.86)

0.239

0.002

79.9%

Sex

 Male

2

0.34 (-0.31, 1.00)

0.301

0.800

0.0%

0.017

 Both

7

0.09 (-0.33, 0.52)

0.675

0.006

66.8%

 Female

2

1.27 (0.58, 1.97)

 < 0.001

0.289

11.2%

Health status

 Metabolic syndrome

1

0.23 (-1.87, 2.33)

0.830

-

-

0.371

 T2DM

4

1.15 (-0.03, 2.34)

0.056

 < 0.001

92.8%

 Hyperlipidemic

4

0.02 (-0.39, 0.44)

0.917

0.650

0.0%

 Hypertension

1

0.00 (-0.49, 0.49)

1.000

-

-

 NAFLD

1

-0.25 (-0.87, 0.37)

0.434

-

-

Subgroup analyses of CLA on serum CRP (mg/L)

 Overall effect

7

0.00 (-0.45, 0.46)

0.976

0.489

0.0%

 

 Baseline CRP (mg/L)

 ≥ 3

4

-0.52 (-1.47, 0.41)

0.273

0.636

0.0%

0.205

 < 3

3

0.17 (-0.36, 0.72)

0.523

0.348

5.4%

Trial duration (week)

 ≥ 12

2

0.00 (-1.44, 1.44)

1.000

1.000

0.0%

0.974

 <12

5

-0.02 (-0.61, 0.56)

0.931

0.245

26.5%

Intervention dose (g/day)

 ≥ 3

2

0.35 (-0.38, 1.10)

0.344

0.248

25.1%

0.159

 <3

5

-0.36 (-1.03, 0.31)

0.292

0.746

0.0%

Baselin BMI (kg/m2)

 Obese (> 30)

3

0.25 (-0.33, 0.84)

0.400

0.405

0.0%

0.166

 Overweight (25–29.9)

3

-0.13 (-0.93, 0.67)

0.748

0.977

0.0%

 Normal (18.5–24.9)

1

-1.48 (-3.22, 0.26)

0.096

-

-

Sex

 Male

2

0.35 (-0.38, 1.10)

0.344

0.248

25.1%

0.159

 Both

5

-0.36 (-1.03, 0.31)

0.292

0.746

0.0%

Health status

 T2DM

1

-0.19 (-1.15, 0.77)

0.699

-

-

0.861

 Hyperlipidemic

5

0.06 (-0.59, 0.73)

0.841

0.285

20.4%

 NAFLD

1

-0.33 (-2.09, 1.43)

0.715

-

-

Subgroup analyses of CLA on serum IL-6 (pg/ml)

 Overall effect

5

-0.44 (-0.86, -0.02)

0.037

0.078

52.3%

 

Intervention dose (g/day)

 ≥ 3

2

-0.32 (-0.66, 0.01)

0.064

0.101

62.8%

0.267

 <3

3

-1.48 (-3.50, 0.53)

0.150

0.169

43.8%

Baselin BMI (kg/m2)

 Obese (> 30)

3

-0.32 (-0.59, -0.05)

0.019

0.257

26.3%

0.059

 Overweight (25–29.9)

1

-0.80 (-1.77, 0.17)

0.107

-

-

 Normal (18.5–24.9)

1

-3.81 (-6.87, -0.74)

0.015

-

-

Sex

 Male

2

-0.32 (-0.66, 0.01)

0.064

0.101

62.8%

0.267

 Both

3

-1.48 (-3.50, 0.53)

0.150

0.169

43.8%

Health status

 T2DM

1

-0.80 (-1.77, 0.17)

0.107

0.023

73.6%

0.772

 Hyperlipidemic

3

-0.41 (-0.94, 0.11)

0.121

-

-

 NAFLD

1

0.08 (-4.85, 5.01)

0.975

-

-

Subgroup analyses of CLA on serum TNF-α (ng/l)

 Overall effect

4

0.26 (-0.16, 0.69)

0.232

0.141

45.0%

 

Subgroup analyses of CLA on serum adiponectin (µg/ml)

 Overall effect

5

-0.12 (-2.41, 2.17)

0.918

 < 0.001

98.7%

 

Trial duration (week)

 ≥ 12

1

-1.10 (-1.49, -0.70)

 < 0.001

-

-

0.269

 <12

4

0.24 (-2.10, 2.59)

0.838

 < 0.001

95.3%

Intervention dose (g/day)

 ≥ 3

4

0.02 (-2.31, 2.35)

0.986

 < 0.001

99.0%

0.513

 <3

1

-3.63 (-14.30, 7.04)

0.505

-

-

Baselin BMI (kg/m2)

 Obese (> 30)

4

0.02 (-2.31, 2.35)

0.986

 < 0.001

99.0%

0.513

 Overweight (25–29.9)

1

-3.63 (-14.30, 7.04)

0.505

-

-

Sex

 Male

2

-0.59 (-1.32, 0.13)

0.110

0.708

0.0%

0.132

 Both

2

1.84 (-1.57, 5.26)

0.290

0.268

18.4%

 Female

1

-1.10 (-1.49, -0.70)

 < 0.001

-

-

Health status

 T2DM

2

-1.10 (-1.49, -0.71)

 < 0.001

0.643

0.0%

 < 0.001

 Hyperlipidemic

2

-0.59 (-1.32, 0.13)

0.110

0.708

0.0%

 Hypertension

1

2.40 (2.25, 2.54)

 < 0.001

-

-

Subgroup analyses of CLA on serum leptin (ng/ml)

 Overall effect

5

-1.69 (-1.80, -1.58)

 < 0.001

0.451

0.0%

 

Trial duration (week)

 ≥ 12

3

-1.08 (-1.87, -0.30)

0.007

0.906

0.0%

0.208

 <12

2

-1.81 (-2.63, -0.99)

 < 0.001

0.282

13.8%

Intervention dose (g/day)

 ≥ 3

4

-1.68 (-1.79, -1.57)

 < 0.001

0.475

0.0%

0.278

 <3

1

-3.34 (-6.32, -0.35)

0.028

  

Baselin BMI (kg/m2)

 Obese (> 30)

4

-1.68 (-1.79, -1.57)

 < 0.001

0.475

0.0%

0.278

 Overweight (25–29.9)

1

-3.34 (-6.32, -0.35)

0.028

  

Sex

 Male

2

-1.35 (-2.94, 0.24)

0.097

0.812

0.0%

0.422

 Both

2

-1.81 (-2.63, -0.99)

 < 0.001

0.282

13.8%

 Female

1

-1.00 (-1.90, -0.09)

0.030

-

-

Health status

 Metabolic syndrome

2

-1.35 (-2.94, 0.24)

0.097

0.812

0.0%

0.913

 T2DM

2

-1.72 (-3.83, 0.39)

0.111

0.141

53.8%

 Hypertension

1

-1.70 (-1.81, -1.58)

 < 0.001

-

-

Subgroup analyses of CLA on serum MDA (mmol/l)

 Overall effect

3

-0.08 (-0.80, 0.62)

0.809

0.001

85.7%

 

Subgroup analyses of CLA on serum ALT (IU/L)

 Overall effect

4

0.48 (-5.11, 6.07)

0.866

0.007

75.5%

 

Subgroup analyses of CLA on serum AST (IU/L)

 Overall effect

4

2.54 (0.06, 5.01)

0.044

0.046

62.4%

 
  1. Abbreviations: WMD Weighted mean differences, CI confidence interval, BMI Body mass index, FBG Fasting blood glucose, HbA1c Hemoglobin A1c, HOMA-IR Homeostatic model assessment for insulin resistance, CRP C-reactive protein, IL-6 Interleukin 6, TNF-α Tumor necrosis factor α, MDA Malondialdehyde, ALT Alanine transaminase, AST Aspartate transaminase
Back to article page

Nutrition Journal

ISSN: 1475-2891

Contact us